{"id":39828,"date":"2025-08-21T13:16:37","date_gmt":"2025-08-21T05:16:37","guid":{"rendered":"https:\/\/flcube.com\/?p=39828"},"modified":"2025-08-21T13:16:38","modified_gmt":"2025-08-21T05:16:38","slug":"haohai-biotech-terminates-ok-lens-distribution-deal-with-brighten-optix-amid-carl-zeiss-acquisition","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39828","title":{"rendered":"Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition"},"content":{"rendered":"\n<p>Shanghai Haohai Biological Technology Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/6826:HKG\">HKG: 6826<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688366:SHA\">SHA: 688366<\/a>) announced the termination of its exclusive distribution agreement for OK lens products with Brighten Optix Corporation. The termination follows Carl Zeiss Vision International GmbH\u2019s plan to acquire 100% of Brighten Optix\u2019s shares via share conversion, resulting in a change of control over Brighten Optix.<\/p>\n\n\n\n<p><strong>Background of the Agreement<\/strong><br>The original agreement, signed in March 2021, granted Brighten Vision, Brighten Optix\u2019s Shanghai branch, exclusive distribution rights for OK lens products, including \u201cmyOK\u201d and \u201cBeishide\u201d, in mainland China until December 31, 2030. Haohai Biotech acted as the procurement platform. In addition, Haohai Biotech\u2019s subsidiary, Shanghai Haohai Pharmaceutical Technology Development Co., Ltd., acquired a 55% stake in Brighten Vision for RMB 25 million, making it a consolidated subsidiary.<\/p>\n\n\n\n<p><strong>Post-Termination Arrangements<\/strong><br>Prior to the formal termination, all parties will continue fulfilling their obligations under the agreements. Brighten Optix will pay Haohai Biotech a termination cooperation subsidy of RMB 80 million. Post-handover, all efforts will be made to facilitate Jinhengtai (Xiamen) Trading Co., Ltd., the minority shareholder of Brighten Vision, signing an equity transfer agreement to transfer its 45% stake. Brighten Vision will ultimately become a wholly-owned subsidiary of Haohai Development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082001492_c-1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025082001492_c.\"><\/object><a id=\"wp-block-file--media-3d39bf69-0b6f-4403-90bd-d7a114bd8074\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082001492_c-1.pdf\">2025082001492_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082001492_c-1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3d39bf69-0b6f-4403-90bd-d7a114bd8074\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Haohai Biological Technology Co., Ltd. (HKG: 6826, SHA: 688366) announced the termination of its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":39833,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,22],"tags":[4302,20,4199,1263,44,1264],"class_list":["post-39828","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-medical-device","tag-brighten-optix","tag-finance","tag-haohai-biological-technology","tag-hkg-6826","tag-ophthalmology","tag-sha-688366"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Haohai Biological Technology Co., Ltd. (HKG: 6826, SHA: 688366) announced the termination of its exclusive distribution agreement for OK lens products with Brighten Optix Corporation. The termination follows Carl Zeiss Vision International GmbH\u2019s plan to acquire 100% of Brighten Optix\u2019s shares via share conversion, resulting in a change of control over Brighten Optix.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39828\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition\" \/>\n<meta property=\"og:description\" content=\"Shanghai Haohai Biological Technology Co., Ltd. (HKG: 6826, SHA: 688366) announced the termination of its exclusive distribution agreement for OK lens products with Brighten Optix Corporation. The termination follows Carl Zeiss Vision International GmbH\u2019s plan to acquire 100% of Brighten Optix\u2019s shares via share conversion, resulting in a change of control over Brighten Optix.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39828\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-21T05:16:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-21T05:16:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2104.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39828#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39828\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition\",\"datePublished\":\"2025-08-21T05:16:37+00:00\",\"dateModified\":\"2025-08-21T05:16:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39828\"},\"wordCount\":210,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39828#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2104.webp\",\"keywords\":[\"Brighten Optix\",\"Finance\",\"Haohai Biological Technology\",\"HKG: 6826\",\"Ophthalmology\",\"SHA: 688366\"],\"articleSection\":[\"Company\",\"Deals\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39828#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39828\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39828\",\"name\":\"Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39828#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39828#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2104.webp\",\"datePublished\":\"2025-08-21T05:16:37+00:00\",\"dateModified\":\"2025-08-21T05:16:38+00:00\",\"description\":\"Shanghai Haohai Biological Technology Co., Ltd. (HKG: 6826, SHA: 688366) announced the termination of its exclusive distribution agreement for OK lens products with Brighten Optix Corporation. The termination follows Carl Zeiss Vision International GmbH\u2019s plan to acquire 100% of Brighten Optix\u2019s shares via share conversion, resulting in a change of control over Brighten Optix.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39828#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39828\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39828#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2104.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2104.webp\",\"width\":1080,\"height\":608,\"caption\":\"Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39828#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Haohai Biological Technology Co., Ltd. (HKG: 6826, SHA: 688366) announced the termination of its exclusive distribution agreement for OK lens products with Brighten Optix Corporation. The termination follows Carl Zeiss Vision International GmbH\u2019s plan to acquire 100% of Brighten Optix\u2019s shares via share conversion, resulting in a change of control over Brighten Optix.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39828","og_locale":"en_US","og_type":"article","og_title":"Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition","og_description":"Shanghai Haohai Biological Technology Co., Ltd. (HKG: 6826, SHA: 688366) announced the termination of its exclusive distribution agreement for OK lens products with Brighten Optix Corporation. The termination follows Carl Zeiss Vision International GmbH\u2019s plan to acquire 100% of Brighten Optix\u2019s shares via share conversion, resulting in a change of control over Brighten Optix.","og_url":"https:\/\/flcube.com\/?p=39828","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-21T05:16:37+00:00","article_modified_time":"2025-08-21T05:16:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2104.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39828#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39828"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition","datePublished":"2025-08-21T05:16:37+00:00","dateModified":"2025-08-21T05:16:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39828"},"wordCount":210,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39828#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2104.webp","keywords":["Brighten Optix","Finance","Haohai Biological Technology","HKG: 6826","Ophthalmology","SHA: 688366"],"articleSection":["Company","Deals","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39828#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39828","url":"https:\/\/flcube.com\/?p=39828","name":"Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39828#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39828#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2104.webp","datePublished":"2025-08-21T05:16:37+00:00","dateModified":"2025-08-21T05:16:38+00:00","description":"Shanghai Haohai Biological Technology Co., Ltd. (HKG: 6826, SHA: 688366) announced the termination of its exclusive distribution agreement for OK lens products with Brighten Optix Corporation. The termination follows Carl Zeiss Vision International GmbH\u2019s plan to acquire 100% of Brighten Optix\u2019s shares via share conversion, resulting in a change of control over Brighten Optix.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39828#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39828"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39828#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2104.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2104.webp","width":1080,"height":608,"caption":"Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39828#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2104.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39828","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39828"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39828\/revisions"}],"predecessor-version":[{"id":39834,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39828\/revisions\/39834"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39833"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39828"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39828"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}